Food News and Research

RSS

Problems controlling common diseases could be hindering efforts to meet key child health goals

Problems controlling common diseases like HIV, heart disease and diabetes in poor countries could be hindering efforts to meet the world's key child health and tuberculosis goals, a new study published in PLoS Medicine has warned.

2 Mar 2010

Daily consumption of chlorella can help maintain healthy body

Americans' dietary habits have been scrutinized for being dependent on processed, refined and incomplete foods. This has left many Americans to reassess the foods they eat and essentially reconstruct their personal food pyramids.

2 Mar 2010

AstraZeneca drafts five principles for companies engaged in social media

AstraZeneca today asked the U.S. Food and Drug Administration (FDA) to adopt guidance that will enable AstraZeneca and others to fully engage in real-time, social media conversations that responsibly provide accurate, balanced information on medicines from a known, identifiable and reliable source.

2 Mar 2010

Consumption of garlic reduces level of potential carcinogenic processes

Researchers have designed a urine test that can simultaneously measure the extent of a potential carcinogenic process and a marker of garlic consumption in humans.

2 Mar 2010

Agilent Technologies, NCFST enter into collaboration to develop new scientific methods for food testing

Agilent Technologies Inc. and the National Center for Food Safety and Technology today announced that they have entered into a collaboration to develop new scientific methods for food testing, with the goal of solving a wide range of persistent problems facing global food supply chains.

2 Mar 2010

Merck's Isentress HIV/AIDS drug pricing: CalSTRS and CalPERS express concern

Today AIDS Healthcare Foundation (AHF) announced that the two largest public pension funds in the nation, the California State Teachers' Retirement System (CalSTRS) and the California Public Employees’ Retirement System (CalPERS), have sent letters to Merck and Co. Pharmaceuticals expressing concern over the company’s pricing for its key HIV/AIDS drug, Isentress—now the most expensive first-line AIDS treatment in the U.S.

2 Mar 2010

Agilent Technologies launches industry’s first transportable GC/MS system delivering laboratory-quality analysis

Agilent Technologies Inc. today introduced the 5975T Low Thermal Mass (LTM) Gas Chromatography/Mass Spectrometry Detector (GC/MSD), the industry’s first commercial transportable GC/MS system that delivers laboratory-quality analysis. Using proprietary LTM technology, Agilent has developed the 5975T LTM GC/MS to be smaller, more rugged and to consume less power than in-lab GC/MS instruments, yet capable of the same high-quality performance in the field.

2 Mar 2010

Canyon Pharmaceuticals announces the availability of Iprivask inhibitor for prevention of DVT

Canyon PharmaceuticalsTM (www.canyonpharma.com) today announced the availability of Iprivask (desirudin for injection), the first direct thrombin inhibitor (DTI) approved in the United States by the Food and Drug Administration for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism in patients undergoing elective hip replacement surgery.

2 Mar 2010

Agilent Technologies announces new lab informatics suite at Pittcon 2010

Agilent’s major new lab informatics suite, the OpenLAB portfolio, is designed to enable customers to easily capture, analyze and share scientific data throughout the lab and across the enterprise. OpenLAB is scalable, open architecture based on industry open standards.

2 Mar 2010

Eliminating sugary beverages and junk foods from schools may help slow childhood obesity

New policies that eliminate sugary beverages and junk foods from schools may help slow childhood obesity, according to a San Francisco State University study released today and published in the March issue of the journal Health Affairs.

2 Mar 2010

New report: Federal spending for public health flat for nearly five years

Trust for America's Health and the Robert Wood Johnson Foundation today released a new report, Shortchanging America's Health: A State-By-State Look at How Public Health Dollars Are Spent, which finds federal spending for public health has been flat for nearly five years, while states around the country cut nearly $392 million for public health programs in the past year, which leaves communities around the country struggling to deliver basic disease prevention and emergency health preparedness services.

2 Mar 2010

Belatacept Biologics License Application: FDA drug advisory committee recommends approval

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee has voted 13 to 5 to recommend approval of belatacept, a selective co-stimulation blocker, for the prophylaxis of acute rejection in de novo kidney transplant patients.

2 Mar 2010

Joint Chiefs Chair visits Haiti to examine aid response

Joint Chiefs of Staff Chair Mike Mullen, who is President Barack Obama's top military adviser, visited Haiti over the weekend to examine relief and rebuilding efforts and meet with local leaders, Agence France-Presse reports. It was his first visit to the country after the earthquake, according to AFP.

2 Mar 2010

FDA's ODAC to review CTI's pixantrone NDA on March 22, 2010

Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's ("FDA") Oncologic Drugs Advisory Committee ("ODAC") will review CTI's New Drug Application ("NDA") for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") on March 22, 2010.

2 Mar 2010

ARIAD Pharmaceuticals' investigational pan-BCR-ABL inhibitor receives FDA and EMA orphan drug designation

ARIAD Pharmaceuticals, Inc. today announced that its investigational pan-BCR-ABL inhibitor, AP24534, has been granted orphan drug designation by both the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the U.S., the orphan designation of AP24534 is for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and in the E.U., its orphan designation is for CML and acute lymphoblastic leukemia.

2 Mar 2010

Massive earthquake hits Chile

"Shell-shocked Chileans struggled to deal with the aftermath of a massive 8.8-magnitude earthquake that ripped through the southern half of the country early Saturday morning," the Wall Street Journal reports.

1 Mar 2010

Acorda Therapeutics' AMPYRA now available in the U.S. and Puerto Rico

Acorda Therapeutics, Inc. today announced that AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg is now available by prescription in the United States and Puerto Rico. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is indicated for use in all types of MS, and can be used either alone or with existing therapies, including disease-modifying agents.

1 Mar 2010

Palliative care helps improve quality, cut end of life care costs

The Philadelphia Inquirer reports on palliative care and focuses on a fairly typical American hospital in Abington.

1 Mar 2010

ChemGenex Pharmaceuticals' OMAPRO review: FDA reschedules ODAC meeting to 22 March, 2010

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration (FDA) has rescheduled the previously postponed Oncologic Drugs Advisory Committee (ODAC) meeting to 22 March 2010.

1 Mar 2010

COMP issues positive opinion for Æterna Zentaris' perifosine orphan medicinal product designation

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation for its compound perifosine from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for the treatment of multiple myeloma.

1 Mar 2010

Food News and Research

Problems controlling common diseases could be hindering efforts to meet key child health goals

Daily consumption of chlorella can help maintain healthy body

AstraZeneca drafts five principles for companies engaged in social media

Consumption of garlic reduces level of potential carcinogenic processes

Agilent Technologies, NCFST enter into collaboration to develop new scientific methods for food testing

Merck's Isentress HIV/AIDS drug pricing: CalSTRS and CalPERS express concern

Agilent Technologies launches industry’s first transportable GC/MS system delivering laboratory-quality analysis

Canyon Pharmaceuticals announces the availability of Iprivask inhibitor for prevention of DVT

Agilent Technologies announces new lab informatics suite at Pittcon 2010

Eliminating sugary beverages and junk foods from schools may help slow childhood obesity

New report: Federal spending for public health flat for nearly five years

Belatacept Biologics License Application: FDA drug advisory committee recommends approval

Joint Chiefs Chair visits Haiti to examine aid response

FDA's ODAC to review CTI's pixantrone NDA on March 22, 2010

ARIAD Pharmaceuticals' investigational pan-BCR-ABL inhibitor receives FDA and EMA orphan drug designation

Massive earthquake hits Chile

Acorda Therapeutics' AMPYRA now available in the U.S. and Puerto Rico

Palliative care helps improve quality, cut end of life care costs

ChemGenex Pharmaceuticals' OMAPRO review: FDA reschedules ODAC meeting to 22 March, 2010

COMP issues positive opinion for Æterna Zentaris' perifosine orphan medicinal product designation

Enhancing confidence in chemical ionization spectrometry data eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News